Endoscopic remission in Crohn’s disease differs by location and is differentially influenced by disease duration

Background Endoscopic remission (ER) is a key therapeutic goal in Crohn’s disease (CD), yet mucosal healing is less frequent in the ileum than in the colon. While longer disease duration reduces the likelihood of ER, whether this effect differs by location is unclear.Methods We conducted a post hoc pooled analysis of individual patient data from four trials (EXTEND, VISIBLE-2, VERSIFY and SEAVUE) via Vivli protocol #10706. A total of 422 patients with baseline Simple Endoscopic Score for Crohn’s Disease (SES-CD) >3 treated with adalimumab, vedolizumab or ustekinumab and with week-52 endoscopic data were included. Patients were categorized as ileal (n = 332) or colonic (n = 303). ER was defined as SES-CD = 0 or <3. Associations between disease duration (<1, <2, <3 years vs. longer) and ER were analyzed using chi-square tests and logistic regression adjusted for treatment.Results Shorter disease duration was associated with higher ER rates overall (SES-CD <3: 35.9% vs. 24.1%, p = 0.018; adjusted OR [aOR] 0.57, 95% CI: 0.32–0.99, p = 0.049). In ileal disease, shorter duration modestly increased ER (31.8% vs. 21.3%, p = 0.048) but was not significant after adjustment (aOR 0.68, 95% CI: 0.39–1.19, p = 0.18). In colonic disease, the association was stronger (SES-CD <3: 39.5% vs. 18.9%, p < 0.001; aOR 0.44, 95% CI: 0.24–0.78, p = 0.005).Conclusions Shorter disease duration predicts higher ER rates, particularly in colonic CD. These findings suggest earlier initiation of biologic therapy may improve healing in colonic disease, whereas ileal healing may be limited by location-specific factors.

Authors

Institutions

Publication Details

Journal
Scandinavian Journal of Gastroenterology
Published
2026-11-16
DOI
https://doi.org/10.1080/00365521.2026.2761270
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Endoscopic remission in Crohn’s disease differs by location and is differentially influenced by disease duration

E C Wong, Walter Reinisch, John K. Marshall, Neeraj Narula et al.
2 links
Scandinavian Journal of Gastroenterology
Inflammatory Bowel Disease
article

Endoscopic remission in Crohn’s disease differs by location and is differentially influenced by disease duration

E C Wong, Walter Reinisch, John K. Marshall, Neeraj Narula, Vipul Jairath, Christopher Ma
article en

Abstract

Background Endoscopic remission (ER) is a key therapeutic goal in Crohn’s disease (CD), yet mucosal healing is less frequent in the ileum than in the colon. While longer disease duration reduces the likelihood of ER, whether this effect differs by location is unclear.Methods We conducted a post hoc pooled analysis of individual patient data from four trials (EXTEND, VISIBLE-2, VERSIFY and SEAVUE) via Vivli protocol #10706. A total of 422 patients with baseline Simple Endoscopic Score for Crohn’s Disease (SES-CD) >3 treated with adalimumab, vedolizumab or ustekinumab and with week-52 endoscopic data were included. Patients were categorized as ileal (n = 332) or colonic (n = 303). ER was defined as SES-CD = 0 or <3. Associations between disease duration (<1, <2, <3 years vs. longer) and ER were analyzed using chi-square tests and logistic regression adjusted for treatment.Results Shorter disease duration was associated with higher ER rates overall (SES-CD <3: 35.9% vs. 24.1%, p = 0.018; adjusted OR [aOR] 0.57, 95% CI: 0.32–0.99, p = 0.049). In ileal disease, shorter duration modestly increased ER (31.8% vs. 21.3%, p = 0.048) but was not significant after adjustment (aOR 0.68, 95% CI: 0.39–1.19, p = 0.18). In colonic disease, the association was stronger (SES-CD <3: 39.5% vs. 18.9%, p < 0.001; aOR 0.44, 95% CI: 0.24–0.78, p = 0.005).Conclusions Shorter disease duration predicts higher ER rates, particularly in colonic CD. These findings suggest earlier initiation of biologic therapy may improve healing in colonic disease, whereas ileal healing may be limited by location-specific factors.

Scandinavian Journal of Gastroenterology
Western University (CA), University of Calgary (CA), Medical University of Vienna (AT), McMaster University (CA)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon